Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57304 | 0.96 | — | — | |
| SCHEMBL13290565 | 0.96 | CHRNA7 (0.42) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL4911003 | 0.96 | — | — | |
| SCHEMBL24496310 | 0.96 | CHRNA7 (0.42) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL104677 | 0.96 | — | — | |
| SCHEMBL1093168 | 0.96 | — | — | |
| SCHEMBL840178 | 0.96 | CHRNA7 (0.42) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL840412 | 0.93 | CHRNA7 (0.41) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL21973884 | 0.93 | CHRNA7 (0.40) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| Bromide SCHEMBL2813935 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CHRNA7 4876/4885SIGMAR1 4779/4885CYP2D6 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.